Third Harmonic Bio Inc. (THRD): Price and Financial Metrics
THRD Price/Volume Stats
| Current price | $11.68 | 52-week high | $12.42 |
| Prev. close | $11.43 | 52-week low | $4.06 |
| Day low | $11.39 | Volume | 217,736 |
| Day high | $12.24 | Avg. volume | 126,948 |
| 50-day MA | $10.00 | Dividend yield | N/A |
| 200-day MA | $8.15 | Market Cap | 475.54M |
THRD Stock Price Chart Interactive Chart >
Latest THRD News From Around the Web
Below are the latest news stories about THIRD HARMONIC BIO INC that investors may wish to consider to help them evaluate THRD as an investment opportunity.
Third Harmonic Bio Inc (THRD) Reports Q3 2023 Financial Results and Continues Progress Towards ...Financial Position Remains Strong with Sufficient Cash Through At Least 2025 |
Third Harmonic Bio Announces Third Quarter 2023 Financial ResultsOn track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with cash and cash equivalents totaling $273.9 million as of September 30, 2023 SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the third quarter ended September 30, 2023. “We |
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Third Harmonic Bio Announces Leadership ChangesSAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023. In his new role, Dr. Ray will continue support the company’s Investigational New Drug (IND) application for THB335, which is expected to be filed during the first half of |
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare ConferenceSAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET. A live audio webcast will be available within the Investors and Media section of the Third Harmonic Bio w |
THRD Price Returns
| 1-mo | 26.13% |
| 3-mo | 20.29% |
| 6-mo | 72.78% |
| 1-year | 168.51% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 6.47% |
| 2023 | 155.12% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...